Our products
A more personalized treatment paradigm requires precision diagnostics to identify the right treatment pathway for each individual patient’s disease
Hexvix® and Cysview®
Based on the Photocure Technology® platform, Photocure has developed and commercialized Hexvix® and Cysview® for use in bladder cancer.
Cysview® is the trademark in the U.S. and Canada, and Hexvix® is the trademark in all other countries.
Hexvix® (hexaminolevulinate 85mg)
Cysview® (hexaminolevulinate HCL)
AssureMDx
AssureMDxTM is a noninvasive, multi-omic, urine-based test which helps improve the early detection of bladder cancer. Utilizing next-generation sequencing and proprietary genomic biomarkers, AssureMDx provides physicians with actionable information to support clinical decision-making and help guide patient care.
Products Divested or Out-Licensed
Own-developed non-urology products divested or out-licensed:
Based on Photocure Technology®, the company developed and commercialized Metvix, a product for non-melanoma skin cancer and actinic keratosis. The product was divested to Galderma S.A. in 2009.
Photocure developed a cosmetic product to improve the overall appearance of skin, visibly reduce the outward signs of aging and minimize the appearance of pores. The product was sold to Bellus Medical (now Crown Aesthetics) in 2017.
Photocure developed Cevira through Phase 1 and Phase 2 trials, and the global rights for development and commercialization were out-licensed to Asieris Meditech Co., Ltd in 2019.
Cevira is a photodynamic drug-device combination product in development for non-surgical treatment of high-grade cervical dysplasia.